Event Abstract

Back to Event

Management of Persistent Idiopathic Facial Pain

Daniela Adamo1*
  • 1 University of Naples Federico II, Department of Neuroscience, Reproductive Sciences and Dentistry, Italy

Persistent idiopathic facial pain (PIFP) is a therapeutic challenge in daily clinical practice because the number of treatment strategies is limited (Benoliel and Gaul, 2017). Psychiatric comorbidity screening is recommended and should be considered in the management plan. Therapeutic trials of PIFP have been reported as efficient but, until now, these have been based on the results of case series and recommendations by experts. Antidepressants and cognitive behaviour therapy provide the best chance of pain relief and an improved quality of life. First line drugs, such as amitriptyline, duloxetine and venlafaxine, and antiepileptics, such as gabapentin or pregabalin, have been considered. These drugs may be prescribed individually or in combination. However, such treatments often have a limited efficacy, with poorly tolerated side effects (Weiss et al., 2017). Other strategies, such as botulinum toxin injections or cannabinoids, are considered as a new treatment route in cases unresponsive to first line drugs. Invasive treatments, such as pulsed radio frequency ablation (PFR) of the sphenopalatine ganglion, peripheral nerve field stimulators (PNFS) and repetitive transcranial magnetic stimulation (rTMS) have also been considered in cases with intractable facial pain (William et al., 2016).

References

1. Benoliel, R., and Gaul, C. (2017). Persistent idiopathic facial pain. Cephalalgia 37, 680-691. 2. Weiss, A.L., Ehrhardt, K.P., and Tolba, R. (2017). Atypical Facial Pain: a Comprehensive, Evidence-Based Review. Curr Pain Headache Rep 21, 8. 3. William, A., Azad, T.D., Brecher, E., Cherry, T., Bernstein, I., Bruce, D.M., Rohrer, S., Smith, Z., William, M., Sabelman, E., Heit, G., Pezeshkian, P., and Sedrak, M. (2016). Trigeminal and sphenopalatine ganglion stimulation for intractable craniofacial pain--case series and literature review. Acta Neurochir (Wien) 158, 513-520.

Keywords: atypical facial pain, Antidepressants, antiepileptics, Cannabinoids, Botulinum toxin injections

Conference: 5th National and 1st International Symposium of Italian Society of Oral Pathology and Medicine., Ancona, Italy, 19 Oct - 20 Oct, 2018.

Presentation Type: oral presentation

Topic: Oral Diseases

Citation: Adamo D (2019). Management of Persistent Idiopathic Facial Pain. Front. Physiol. Conference Abstract: 5th National and 1st International Symposium of Italian Society of Oral Pathology and Medicine.. doi: 10.3389/conf.fphys.2019.27.00075

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 28 Nov 2018; Published Online: 09 Dec 2019.

* Correspondence: Dr. Daniela Adamo, University of Naples Federico II, Department of Neuroscience, Reproductive Sciences and Dentistry, Napoli, Campania, 80138, Italy, marcomascitti86@hotmail.it